MediWound Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.9%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$23.7Mnext fiscal year
FY EPS (est.)
-$2.23next fiscal year
Monitoring Framework
Key Performance Indicators
Annual Revenue Annually17MTarget: 24000000 to 26000000
Quarterly Revenue Quarterly1.5MTarget: Weighted towards second half of 2026
Cash and Cash Equivalents Quarterly44.7MTarget: Sufficient liquidity to fund operations and clinical trials
Watch Items
- EscharEx Phase III VALUE Study Enrollment and TimelinesTrigger: Delays in patient recruitment or trial milestones beyond Q3 2028 commercial targetAction: Re-evaluate clinical trial site operations, expand European site enrollment, and adjust long-term cash burn projections.
- BARDA Contract Execution and NexoBrid ProcurementTrigger: Delays in government-related procurement orders or development service revenuesAction: Coordinate with distributor Vericel to accelerate operational readiness and adjust second-half revenue weighting assumptions.
Research as of 20 Jun 2026